A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch

Published:2014-08-08 Issue:4 Volume:167 Page:466-477
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Awan Farrukh T.¹,Hillmen Peter²,Hellmann Andrzej³,Robak Tadeusz⁴,Hughes Steven G.⁵,Trone Denise⁵,Shannon Megan⁵,Flinn Ian W.⁶,Byrd John C.¹,

Affiliation:

1. The Ohio State University Comprehensive Cancer Center; Columbus OH USA

2. St James's Institute of Clinical Oncology; Leeds UK

3. Department of Haematology; Medical University of Gdańsk; Gdansk Poland

4. Medical University of Lodz; Lodz Poland

5. Biogen Idec Inc.; Nashville TN USA

6. The Sarah Cannon Research Institute; Nashville TN USA

Funder

Lymphoma Research Foundation

Biogen Idec

D Warren Brown Foundation

Leukemia Lymphoma Society

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13061/fullpdf

Reference29 articles.

1. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia;Byrd;Clinical Cancer Research,2007

2. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia;Byrd;Blood,2010

3. B-cell chronic lymphocytic leukemia: a bird of a different feather;Caligaris-Cappio;Journal of Clinical Oncology,1999

4. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment;Cheson;Blood,1996

5. Antibody therapy for chronic lymphocytic leukemia;Christian;Seminars in Hematology,2008

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19

2. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

3. Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia;Therapeutic Advances in Medical Oncology;2024-01

4. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review;Frontiers in Oncology;2023-02-07

5. Solid Swellings of the Anterior Triangle: Cervical Lymphadenopathy;Lateral Neck Swellings;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3